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The aim of this study was to develop and evaluate a multiparticulate modified release system, composed 
of minitablets with a sustained release matrix system coated with a pH-dependent release polymer, 
using mesalamine as a model drug. Polyox® WSR 1105 was the polymer used in the matrix system and 
Eudragit® L30D55 was used as a pH-dependent polymer. The minitablets (with 20%, 30% or 40% Polyox® 
concentration) were prepared by dry granulation, which led to good quality minitablets. The developed 
minitablets were coated in a fluidized bed at 8% of the coating level. Dissolution studies were performed 
in media that simulated the gastrointestinal tract (pH 1.4, 6.0 and 7.2) and showed that formulations with 
higher Polyox® concentrations were capable of retaining the drug release in pH 1.4. All formulations 
prolonged the drug release and presented zero-order kinetic behaviour. The Korsmeyer-Peppas model 
demonstrated that formulations with 20% or 30% of polymer exhibited anomalous transport behaviour, 
whilst the 40% sample exhibited super case II model transportation. Dissolution efficiency showed that 
only the formulations containing 20% and 40% polymer could be considered statistically different.
Uniterms: Mesalamine/modified release/evaluation. Minitablets coated/modified release/evaluation. 
Polyethylene oxide/drugs coating. Drugs/modified release.
O presente trabalho teve como objetivo desenvolver e avaliar um sistema multiparticulado de liberação 
modificada, composto por minicomprimidos com sistema matricial de liberação prolongada revestidos 
com polímero de liberação pH-dependente, utilizando mesalazina como fármaco modelo. Polyox® WSR 
1105 foi o polímero utilizado no sistema matricial e Eudragit® L30D55 foi utilizado como polímero 
pH-dependente. Os minicomprimidos (com 20%, 30% e 40% de concentração de Polyox®) foram 
preparados por granulação via seca, gerando minicomprimidos de boa qualidade. Os minicomprimidos 
desenvolvidos foram revestidos em leito fluidizado a 8% de nível de revestimento. Efetuou-se o estudo 
de dissolução em meios que simulam o trato gastrointestinal (pH 1,4, 6,0 e 7,2) e as formulação contendo 
maiores concentrações de Polyox® foram capazes de reter a liberação do fármaco em pH 1,4. Todas as 
três formulações apresentaram liberação prolongada e comportamento cinético de ordem zero. O modelo 
de liberação de Korsmeyer-Peppas mostrou que as formulações com 20% e 30% de polímero apresentam 
comportamento de transporte anômalo, enquanto a com 40%, transporte super caso II. A eficiência de 
dissolução mostrou que somente as formulações com 20% e 40% de concentração do polímero foram 
consideradas estatisticamente diferentes.
Unitermos: Mesalazina/liberação prolongada/avaliação. Minicomprimidos revestidos/liberação 
prolongada/avaliação. Óxido de polietileno/revestimento de fármacos. Fármacos/liberação modificada.
INTRODUCTION
Solid dosage forms are the most frequently used 
for oral administration, and tablets represent the most 
common pharmaceutical form used (Allen, Popovich, 
Ansel, 2005). Oral dosage forms can be classified into two 
broad groups: single unit dosage forms, as capsules and 
tablets, and multiple unit dosage forms, such as granules, 
pellets and minitablets (Lopes et al., 2006).
Multiparticulate dosage forms present multiple 
advantages over single unit dosage forms, demonstrated 
as flexibility during formulation development and 
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therapeutic benefits for the patients, including increased 
bioavailability, reduced risk of systemic toxicity due 
to dose dumping and reduced risk of local irritation, 
besides predictable gastric emptying (Kramar, Turk, 
Vrecer, 2003).
Although the oral dosage form is the most widely 
accepted route of administration, the gastrointestinal tract 
presents several barriers to drug delivery (Gupta, Beckert, 
Price, 2001). In this way, pharmaceutical technology has 
played a fundamental role in the investigation of systems 
that efficiently deliver a drug to its site of action (Déo, 
Andreazza, Possamai, 2011). The use of modified release 
allows a drug to be delivered at a rate dictated by the needs 
of the body over the period of treatment (extended release) 
and also avoids or directs the drug to specific sites, as in 
delayed release (Nagaraju et al., 2010).
Extended release may be achieved based on 
modifying drug dissolution by controlling the access of 
biologic fluid to the drug. This control can be achieved 
through barrier coating, micro encapsulation, complex 
formation, ion exchange resins, or by embedding the 
drug in a slowly eroding or hydrophilic matrix system. In 
delayed release dosage forms, enteric coating is generally 
used to protect drugs from the gastric acidic environment 
(Allen, Popovich, Ansel, 2004).
Minitablets are tablets with a diameter between 2 
and 3 mm (Lennartz, Mielck, 1998). Their production uses 
tableting technique, which is an attractive alternative to 
pellet production, as the presence of solvents is avoided 
and, due to the manufacturing process, defined sizes and 
strengths can be easily produced, with little variability 
within and between batches (Funaro et al., 2010). The 
advantages of multiparticulate systems can be associated 
with the advantages of modified drug release, enabling the 
achievement of systems that efficiently deliver the drug 
to its site of action.
Mesalamine is mainly used in the treatment of 
inflammatory bowel disease, such as ulcerative colitis 
and Crohn’s disease, due to its local effect on intestinal 
and colonic mucosa and to its few side effects (Qureshi, 
Cohen, 2005). Mesalamine’s mechanism of action is 
only partially understood, although it is accepted that its 
effect occurs locally in the intestinal mucosa by inhibiting 
cyclooxygenase and lipooxygenase, thus decreasing the 
production of prostaglandins and leukotrienes (Silva, 
2006). In this way, the highest efficacy and least toxicity 
occur when the drug is specifically delivered to the 
affected area (Canevari et al., 2009).
The aim of this  research was to develop a 
multiparticulate system with delayed and extended release 
formed by coated minitablets made of a hydrophilic matrix. 
Mesalamine was used as model drug; the minitablets were 
made of hydrophilic polymer polyethylene-oxide and 
coated with a pH-dependent metacrylic derived polymer. 
The drug release profile was evaluated and the release 
kinetics obtained.
MATERIAL AND METHODS
Pharmaceutical-grade raw materials were obtained 
from local suppliers and were used as received. The 
minitablets were prepared with anhydrous mesalamine 
(Deg Ltda, São Paulo, Brazil). The polyethylene oxide 
(Polyox® WSR 1105, molecular weight 0.9.106) was 
kindly donated by Colorcon (Sao Paulo, Brazil). The 
other excipients were 200 microcrystalline cellulose 
(Microcel® 200, Blanver Ltda, Sao Paulo, Brazil), 
magnesium stearate (Faci Spa, Carasco, Italy), and 
colloidal silicon dioxide (Blanver Ltda, São Paulo, 
Brazil). The coating was made via aqueous dispersion 
of the methacrylic-derived Eudragit® L30D55 (Degussa 
Ltda, Sao Paulo, Brazil).
Preparation of the granules
The selected technique for minitablet production 
was dry granulation. Formulations containing mesalamine, 
polyethylene oxide, magnesium stearate and colloidal 
silicon dioxide, as shown in Table I, were mixed in a 
plastic bag for 15 min. The mixtures were compressed 
into 400 mg slugs using an eccentric compression machine 
(EK0, ERweka GmbH, Heusenstamm, Germany) with a 
13 mm planar punch. The slugs were crushed in a mortar 
and pestle and the granules were sieved on metal sifters 
(Bertel, Caieiras, Brazil) using 355, 500 and 710 µm 
opening sieve mesh (42, 32 and 24 Tyler series sieve). 
Granules with a size fraction of 355–500 µm were 
withheld for powder flow analyses.
TABLE I – Composition of minitablet formulations
Component F1 (%) F2(%) F3(%)
Mesalamine 40.0 40.0 40.0 
Polyox® WSR 1105 20.0 30.0 40.0 
Mycrocrystalline cellulose 
200
38.0 28.0 18.0
Colloidal silicon dioxide 0.5 0.5 0.5 
Magnesium stearate 1.5 1.5 1.5
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Powder flow
Determination of the static angle of repose was 
performed according to the method proposed by Prista, 
Alves, Morgado (1991) and Staniforth (2005) using the 
fixed-height funnel method (measuring the height and the 
radius of the cone formed when 30 g of the granule was 
allowed to flow gently trough the funnel). Bulk density 
was calculated from the volume of 10 g of granules 
occupying a 50 mL graduated cylinder, while for the 
tap density determination; the cylinder was tapped until 
no measurable change in volume was observed. The 
compressibility index and Hausner ratio were calculated 
based on bulk and tap density (Compressibility index = 
(tapped – bulk) x 100/tapped; Hausner ratio = tapped/
bulk) as described in the United States Pharmacopeia 
(USP 31, 2008). All powder flow analyses were made 
in triplicate.
Production of minitablets
The granules (355 – 500 µm) were compressed 
using an eccentric compression machine (EK0, Erweka 
GmbH, Heusenstamm, Germany) equipped with a triple 
planar punch 3 mm in diameter and manual feeding. A 
500 g batch was prepared (for each formulation) and each 
minitablet weighed approximately 27 mg.
Coating of minitablets
The formulations, previously warmed to 40 °C, were 
coated in a fluidized bed (LM-FBD 5.0 Labmaq do Brasil 
Ltda, Ribeirao Preto, Brazil – inlet temperature of 40 °C) 
and a spray rate was 2.5 ml.min-1. After 10 min, the spray 
rate was increased to 4.0 ml.min-1. The coating solution 
(Eudragit® L-30D55, 10% w/v) was applied until there 
was an 8% weight gain.
Evaluation of the minitablets physical 
characteristics
An evaluation of physical characteristics was 
performed for both uncoated and coated minitablets. The 
parameters evaluated were: weight variation, friability, 
diameter and thickness according to specifications of the 
Brazilian Pharmacopeia (2010).
Drug content in minitablets
The content of mesalamine in each batch (samples 
of 100 mg) was determined by ultraviolet spectroscopy 
(UV-1601 UV-Visible Spectrophotometer Shimadzu) at 
303 nm (Moharana et al., 2011).
Coating level
The level of coating was calculated by subtracting 
the content of mesalamine in coated minitablets from that 
found in uncoated minitablets (Amighi, Moes, 1996).
Degree of swelling of tablets
The degree of swelling (H%) was investigated 
under conditions that simulated the gastrointestinal tract 
according to the methodology described by Moustafine 
et al. (2006).
Dissolution profile
Drug release from the formulations were evaluated 
on a Hanson® SR6 dissolution tester (apparatus 2, 
100 rpm, 37 °C ± 0.5 °C) (Hanson Co., Chatsworth, 
USA) for twelve hours, divided into three stages (pH 1.4, 
6.0 and 7.2) according to the methodology described by 
Chuong, Christensen and Ayres (2008). Samples of 5 mL 
were withdrawn (with replacement) at different times. 
The concentration of dissolved drug was measured by 
spectrophotometry (Shimadzu UV-1601, Kyoto, Japan) 
at a wavelength of 302 nm for the first stage, and 330 nm 
for the second and third stages. Sample quantification was 
based on previously constructed analytical curves (one 
for each pH) and submitted to regression analysis. Linear 
relations were obtained in the concentration interval 
5-100 µg.mL-1 with correlation coefficients (r) of 
0.9998 (pH 1.4), 0.9997 (pH 6.0) and 0.9999 (pH 7.2).
The profiles obtained were compared using model-
independent and model-dependent methods. As a model-
independent method, the dissolution efficiency (DE%) was 
calculated from the area under the dissolution curve at time 
t (measured using the trapezoidal rule) and expressed as a 
percentage of the rectangle described by 100% dissolution 
in the same time (Khan, 1975). The DE% values were 
submitted to statistical comparison using analysis variance 
(ANOVA-single factor) in order to detect significant 
differences between the formulations, and then by Tukey’s 
test. In the model-dependent approach, the release data 
were fitted to four kinetic models: zero-order, first-model, 
Higuchi model and Korsmeyer-Peppas model. The last 
model was calculated according to Equation 1 (Pillay, 
Fassihi, 1999):
  Equation 1
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where t-l is the time excluding lag time, M(t-l) is the amount 
of drug dissolved in time t-l, M0 the initial amount of 
drug, KK the release constant and n, the release exponent, 
indicates the release mechanism (Peppas, 1985).
RESULTS AND DISCUSSION
The powder flow evaluation is one of the most 
important parameters in the development of a solid 
dosage form, because commercial production requires a 
continuous flow of powder mixes during the manufacturing 
process (Yang, Venkateshi, Fassihi, 1996). Because 
of the narrow diameter of the compression die used 
to obtain minitablets (3 mm), granules with excellent 
flow properties are required (Brabander et al., 2000). 
According to the literature, excellent flow properties are 
seen for powders with an angle of repose between 25° 
and 30°, compressibility index below 10% and Hausner 
ratio below 1.11 (USP 31, 2008). All the formulations 
under evaluation had an angle of repose between 26° 
and 29°, compressibility index less than 6% and Hausner 
ratio below 1.05. Their excellent flow properties were 
also proved by the narrow weight distribution of the 
minitablets and their low friability, since all formulations 
had coefficient of variation values less than 5% relative to 
their mean weight and friability less than 1%. These results 
demonstrated the suitability of all formulation mixtures 
used to produce minitablets.
The minitablets obtained also had suitable physical 
characteristics of thickness, diameter, and weight 
variation, with coefficient of variation values less than 
5% (n=20). 
Table II contains the results determined for 
mesalamine content in 100 mg samples of the uncoated 
(F1, F2, and F3) and coated minitablets (F1R F2R and 
F3R). The content of the uncoated formulations was in 
agreement with the formulations (Table I) and was used 
as a reference for determining the coating level of F1R, 
F2R and F3R. As expected, there was a reduction in 
mesalamine content in the coated formulations, due to the 
level of coating applied. The values for the coating level 
(mg%) for the formulations were in accordance with the 
planned weight gain (8%).
The conditions of the coating process were chosen 
based on a previous study of Déo, Andreazza and Possamai 
(2011) that analysed mesalamine pellets coated with 
Eudragit®. The coating process was performed with 
a varying spray rate because, as the minitablets gain 
a coating, the adhesion of the film to the minitablets 
increases. Thus, the process started with a low spray rate 
that was increased over time, optimizing the processing 
time.
According to the Brazilian Pharmacopeia (2010), 
delayed release presents less than 10% of drug released at 
the end of the acid stage (120 min). This characteristic is 
seen in F2R and F3R, with a drug release of approximately 
3.5% and 2.5%, respectively, after 120 min. The uncoated 
minitablets attained over 85% release in 120 minutes of 
testing, behaving as an immediate release dosage form. 
The F1R formulation had a drug release at the end of the 
acid release period of approximately 14%, hence cannot 
be considered a delayed release formulation. This may 
occur because the F1R formulation had less Polyox®, 
which implies fewer obstacles to release of the drug in 
the matrix.
The calculation of the release kinetics showed 
that the three formulations presented extended release, 
since the most suitable kinetic model was zero-order, 
as demonstrated in Table III. The zero-order kinetic 
model is considered the ideal model for extended release 
formulations, as pharmaceutical dosage forms following 
this profile release the same amount of drug per unit of 
time (Costa, Sousa Lobo, 2001). As the mechanism of 
mesalamine release from the matrix minitablet is not 
well-known, it was calculated using the Korsmeyer-
Peppas model, which relates drug release exponentially 
to the elapsed time. The magnitude of the exponent n 
indicates the release mechanism. In the present study 
TABLE II – Content of mesalamine and coating level
Content of mesalamine (mg %*) Coating level (mg %) Coating level (%)
F1 38.70 ± 0.53 - -
F2 40.17 ± 0.31 - -
F3 39.64 ± 1.33 - -
F1R 35.62 ± 0.04 3.08 7.96
F2R 36.88 ± 0.05 3.29 8.19
F3R 36.51 ± 0.04 3.13 7.89
*mean ± coefficient of variation (CV); n=3
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(cylindrical shape), the limits considered were n=0.45 
(indicating a classical Fickian diffusion-controlled 
drug release), n=0.89 (case II transport), 0.45<n<0.89 
(anomalous transport) and n>0.89 (super case II 
transport).
The Korsmeyer-Peppas model showed that F1R 
and F2R presented anomalous transport and F3R a 
super case II transport (Table III). Anomalous transport 
indicates that the solvent diffusion rate and polymer 
relaxation occur are of the same order of magnitude, 
which means that the transport corresponds to coupled 
drug diffusion in the hydrated matrix and polymer 
relaxation. In super case II transport, the rate of solvent 
diffusion is greater and is the determining factor of the 
diffusion (Agnes, Ortega, 2003).
The results obtained for DE in percent (DE%) are 
shown in Table IV. To infer the similarity between the 
formulations, the DE% assessment entailed statistical 
analysis, performed between means, using ANOVA. 
Values of F=17.6631 (Fcritical=3.1059) and p-value = 
3.65.10-5 were obtained, which means the formulations 
are considered statistically different. Therefore, the 
means of treatment were compared using Tukey’s test at 
5% probability and it was found that F1R and F3R were 
statistically different.
Polyox® swelling occurs immediately upon 
hydration of the polymer. As the dry polymer becomes 
hydrated, the mobility of the polymer chains grows, 
increasing the hydrodynamic volume of the polymer 
compact, which allows the compact to swell. As polymer 
chains become more hydrated and the gel becomes 
more diluted, the disentanglement concentration may be 
reached, resulting in simultaneous swelling, dissolution, 
and erosion (Todd, L’Hote-Gaston, Sheick, 2008). 
The swelling behaviours of the three different kinds of 
minitablets are shown in Figure 2. The formulations show 
almost no increase in weight during the first 60 min due 
to the pH at this stage (pH 1.4), since the minitablets are 
coated with a pH-dependent polymer that dissolves at pH 
above 5.5. After 60 min, the medium pH was increased 
TABLE III – Pearson’s correlation coefficient (r), following linear dissolution data, and release exponent (n) (n=6)
Formulation
Zero-order First-order Higuchi Korsmeyer-Peppas
r R r r n
F1R 0.9767 0.9601 0.9685 0.9667 0.4623
F2R 0.9995 0.9915 0.9982 0.9226 0.7637
F3R 0.9913 0.9831 0.9881 0.9876 1.1121
TABLE IV – Dissolution efficiency of formulations F1R, F2R 
and F3R
Formulation DE%*
F1R 50.67 ± 1.53
F2R 48.33 ± 0.57
F3R 44.67 ± 1.15
* mean ± SD; (n=6)
FIGURE 1 – Dissolution profiles of uncoated and coated formulations (mean ± SD; n=6).
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to 6.8 and the formulations presented increased weight 
(swelling), which was more pronounced in F3R. This 
characteristic was expected, since F3R has more Polyox® 
in its formulation and the polymer is hydrophilic.
After 120 minutes of testing, all the formulations 
presented a decrease in the degree of swelling, indicating 
the occurrence of erosion. This erosion process can be 
supported by the n value found for the formulations (Table 
III). F1R and F2R presented an anomalous transport, 
indicating a joint action between the processes of swelling 
and erosion, as seen by Maggi et al. (2002) in a study 
using Polyox® WSR 1105, in which it was suggested 
that the rate of swelling and erosion are similar and, 
therefore, both mechanisms are effective in controlling 
drug release. F3R presented super case II transport, which 
also indicates that drug release occurs by both swelling 
and erosion; however, the rate of water uptake occurs 
faster than polymer relaxation, promoting the erosion of 
the system (Steingraber, Schtoltz, Rodrigues, 2008). This 
characteristic may be a consequence of the greater amount 
of hydrophilic polymer, which has a high affinity for the 
dissolution tester medium.
It has been observed (Vendruscolo, 2005) that a 
higher proportion of polymer matrix reduces the rate of 
drug release, since a larger amount of polymer increases 
the degree of swelling, resulting in an increase in the 
drug diffusional path and consequent delay in the release 
rate. However, marked differences between the three 
formulations studied were not seen, suggesting that the 
prolongation of drug release in minitablets containing a 
large amount of drug in their composition is not greatly 
affected by variations in the amount of hydrophilic 
polymer used.
CONCLUSION
This study proposed the development of minitablets 
containing mesalamine with modified drug release: delayed 
release and extended release. The minitablets contained 
20%, 30% or 40% Polyox® to sustain drug release and were 
coated with Eudragit® L30D55. The formulations with 30% 
or 40% of the polymer presented delayed release and all 
formulations tested presented an extended release with zero-
order release kinetics. However, the dissolution profile was 
not greatly affected by the variations in the polymer used, 
and only the formulations with the lowest and the highest 
concentration of Polyox® were considered statistically 
different. The Korsmeyer-Peppas model suggested that both 
swelling and erosion mechanism influence drug release.
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